Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|May 3, 2017
Factors That Could Impact Specialty Pharmacy Patients
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses high drug costs and the specialty pharmacy patient.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses high drug costs and the specialty pharmacy patient.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
3
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
4
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
5